Elicera – Pre-clinical proof-of-concept data for iTank
Please join this event with Elicera’s CDO Dr. Di Yu where he will present pre-clinical proof-of-concept data for the company’s technology platform I-TANK.
Data will be released the October the 19th.
The I-TANK platform has been developed to improve the function of CART cells but also to activate a separate attack by the immune system against the entire set of relevant targets on cancer cells via the patient's own so-called killer T-cells," says CEO Jamal El-Mosleh. “We use the technology to strengthen our own drug candidates, including next generation of oncolytic viruses, which is why it is considered one of our most important assets.
The company develops four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields.